Serum IgM reduction caused by these therapies may mitigate the benefit, particularly after long term administration, by increasing the risk for infection in patients susceptible to infection, increased risk for atherosclerosis, or even exacerbate autoimmunity. Here, CD40LG is linked to Autoimmunity.